The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / ACR Insurance Subcommittee Focuses on Coverage & Reimbursement

ACR Insurance Subcommittee Focuses on Coverage & Reimbursement

January 16, 2020 • By Ellen M. Gravallese, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
The Good Brigade / offset

The Good Brigade / offset

On behalf of the ACR, I wish you happiness, prosperity and, above all, good health in this new decade.

You Might Also Like
  • The ACR Insurance Subcommittee Advocates for Fair Payer Policies
  • ACR Insurance Subcommittee Responds to Payer Policies
  • Protect Your Practice: Action Update From the ACR’s Insurance Subcommittee
Explore This Issue
January 2020
Also By This Author
  • Leveraging the ACR’s RISE Registry for Research

Now that the holidays are behind us and 2020 has launched, the ACR’s dedicated volunteers and staff are working collaboratively to achieve many ambitious initiatives to ensure the College’s dynamic and bright future.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

A few weeks ago in The Rheumatologist, I shared my thoughts about the ACR’s goals for the coming year and beyond. Ensuring access to effective and safe medications for our patients to control disease activity and restore and retain quality of life remains a pressing concern for rheuma­tologists and members of the interprofessional team. Although we see more medications than ever before being approved for the treatment of rheumatic diseases, our patients cannot benefit if these treatments are out of reach.

Some concerning coverage gaps and re­imbursement challenges that affect our members and patients have arisen. In many states, we are seeing resistance from major payers not only to covering medications critical for our patients, but also to cover consulting services. What is the ACR doing to fight back on behalf of our patients?

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The ACR Insurance Subcommittee (ISC), a branch of the Committee on Rheumatologic Care, has been working diligently with its staff to address urgent coverage and reimbursement issues that put the health of our patients and the fiscal viability of many rheumatology practices in jeopardy. The ISC is engaged in immediate, persistent advocacy to address these challenges with specific payers, and remains engaged with stakeholders on all sides of these issues.

Coverage for Physician-Administered Drugs

One ongoing issue that affects both rheuma­tology practices and our patients is coverage for many commonly prescribed, infusible, biologic drugs. Some payers have recently changed policies to require patients first fail self-administered formulations before providing coverage for infusible biologics. Despite advocacy efforts by the ISC against this change, many patients continue to face coverage delays.

At the ACR, we believe collaborative advocacy is a powerful tool. The ACR recently led a coalition of rheumatology organizations, including 25 state rheumatology societies, the Coalition of State Rheumatology Organizations (CRSO), the Arthritis Foundation, the Association of Women in Rheumatology (AWIR) and the National Organization of Rheumatology Managers (NORM), to advocate for a permanent cessation of a major insurer’s proposed fail-first policies. The ISC has also spoken directly to insurance com­panies and requested they provide advance notification to physicians before enacting any changes to coverage of these important therapies for our patients.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The ACR is staying fully engaged with payers about fail-first policies. We have agreed to assist one major insurer in developing a list of exceptions criteria that would help protect patients and support clinical decision making by ensuring patients can be excluded from the step requirements when necessary. We have also insisted that payers who enact fail-first policies grandfather coverage for any patients on existing therapy, so that they may continue with uninterrupted access to the medications they need to control their disease.

Pages: 1 2 3 | Single Page

Filed Under: Legislation & Advocacy, President's Perspective Tagged With: Centers for Medicare & Medicaid Services, Insurance SubcommitteeIssue: January 2020

You Might Also Like:
  • The ACR Insurance Subcommittee Advocates for Fair Payer Policies
  • ACR Insurance Subcommittee Responds to Payer Policies
  • Protect Your Practice: Action Update From the ACR’s Insurance Subcommittee
  • Insurance Subcommittee to the Rescue

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)